We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Backs Paladin’s Impavido for Parasitic Diseases
FDA Panel Backs Paladin’s Impavido for Parasitic Diseases
October 18, 2013
FDA advisors Oct. 18 enthusiastically endorsed Paladin’s leishmaniasis drug, Impavido, saying it would provide U.S. patients with the first oral treatment proven to combat three complex and debilitating parasitic diseases.